Roivant Sciences (NASDAQ:ROIV) CFO Richard Pulik Sells 125,000 Shares of Company Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 125,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $41.20, for a total transaction of $5,150,000.00. Following the transaction, the chief financial officer directly owned 269,681 shares of the company’s stock, valued at $11,110,857.20. This represents a 31.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Richard Pulik also recently made the following trade(s):

• On Wednesday, November 11th, Richard Pulik sold 175,000 shares of Roivant Sciences stock. The shares were sold at an average price of $41.85, for a total transaction of $7,323,750.00.

Roivant Sciences Price Performance

Shares of ROIV opened at $39.99 on Friday. The business’s 50 day moving average price is $37.20 and its 200-day moving average price is $32.16. Roivant Sciences Ltd. has a 52 week low of $19.96 and a 52 week high of $42.50.

Wall Street Analysts Forecast Growth

Several research firms have commented on ROIV. UBS Group set a $55.00 target price on Roivant Sciences in a report on Wednesday, September 9th. Wolfe Research downgraded Roivant Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, October 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. HC Wainwright upped their price target on shares of Roivant Sciences from $47.00 to $48.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $46.64.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Alpine Bank Wealth Management purchased a new position in Roivant Sciences in the 3rd quarter worth approximately $25,000. Compass Financial Management LLC bought a new position in Roivant Sciences in the 3rd quarter valued at approximately $37,000. Parallel Advisors LLC boosted its stake in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after purchasing an additional 520 shares during the last quarter. Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after purchasing an additional 441 shares during the last quarter. Finally, Root Financial Partners LLC bought a new stake in shares of Roivant Sciences in the 3rd quarter worth $120,000. Institutional investors own 64.76% of the company’s stock.

Key Roivant Sciences News

Here’s some of the latest news about ROIV:

• Positive Sentiment: HC Wainwright raised its price target on ROIV, and recent analyst commentary has been bullish. A separate analysis points to pipeline momentum and potential contributions from trial results and drug-launch revenue. HC Wainwright price-target article Analyst commentary Pipeline momentum analysis
• Neutral Sentiment: A recent article discusses how clinical-trial outcomes and drug-launch revenue could affect Roivant’s stock, but the provided headline does not specify new trial results or revenue figures. Article on trial wins and launch revenue
• Negative Sentiment: CEO Eric Venker sold about 188,000 shares, reducing his position by 18.81%; the transaction was made under a pre-arranged Rule 10b5-1 plan. CFO Richard Pulik sold 125,000 shares on November 10 and another 175,000 on November 11, reducing his position by 44.08%. The sizable insider sales could pressure sentiment, though Venker’s sale was pre-scheduled. CEO SEC filing CFO SEC filing

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.